MX337421B - Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida. - Google Patents
Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida.Info
- Publication number
- MX337421B MX337421B MX2010006593A MX2010006593A MX337421B MX 337421 B MX337421 B MX 337421B MX 2010006593 A MX2010006593 A MX 2010006593A MX 2010006593 A MX2010006593 A MX 2010006593A MX 337421 B MX337421 B MX 337421B
- Authority
- MX
- Mexico
- Prior art keywords
- adp
- poly
- present
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical class N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012623 DNA damaging agent Substances 0.000 abstract 1
- 230000033616 DNA repair Effects 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1033308P | 2008-01-08 | 2008-01-08 | |
| PCT/GB2009/000041 WO2009087381A1 (en) | 2008-01-08 | 2009-01-08 | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2010006593A MX2010006593A (es) | 2010-12-21 |
| MX337421B true MX337421B (es) | 2016-03-04 |
Family
ID=40404013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010006593A MX337421B (es) | 2008-01-08 | 2009-01-08 | Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8436185B2 (https=) |
| EP (1) | EP2240466B1 (https=) |
| JP (1) | JP5989965B2 (https=) |
| KR (1) | KR101653548B1 (https=) |
| CN (2) | CN106008460B (https=) |
| AU (1) | AU2009203598B2 (https=) |
| BR (1) | BRPI0906020A2 (https=) |
| CA (1) | CA2711491C (https=) |
| ES (1) | ES2548131T3 (https=) |
| FR (1) | FR18C1020I2 (https=) |
| IL (1) | IL206201A (https=) |
| MX (1) | MX337421B (https=) |
| NL (1) | NL300938I2 (https=) |
| NZ (1) | NZ586675A (https=) |
| WO (1) | WO2009087381A1 (https=) |
| ZA (1) | ZA201003902B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2340244A4 (en) | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
| ES2578990T3 (es) | 2009-03-21 | 2016-08-03 | Sunshine Lake Pharma Co., Ltd. | Derivados de amino éster, sales de los mismos y métodos de uso |
| EP2534153B2 (en) | 2010-02-12 | 2024-05-22 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| EA201792184A1 (ru) | 2015-04-01 | 2018-04-30 | Анаптисбайо, Инк. | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) |
| JP6727660B2 (ja) * | 2015-09-30 | 2020-07-22 | 国立大学法人東北大学 | 糖尿病性腎症の判定マーカー |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| CN107663190B (zh) * | 2016-07-29 | 2020-06-09 | 钟桂发 | 一种尼拉帕尼及其中间体的制备方法以及中间体化合物 |
| BR112019001398A2 (pt) | 2016-07-29 | 2019-05-07 | Janssen Pharmaceutica Nv | métodos para tratamento de câncer de próstata |
| CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| CA3041684C (en) | 2016-11-01 | 2023-09-26 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| MX2019008208A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-tim-3. |
| BR112019020211A2 (pt) * | 2017-03-27 | 2020-04-22 | Tesaro, Inc. | composições de niraparib |
| KR20190130625A (ko) * | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| JP7118347B2 (ja) * | 2017-04-04 | 2022-08-16 | コンビフォス カタリスツ インコーポレイテッド | 重水素化（ｓ）２－（４－（ピペリジン－３－イル）フェニル）－２ｈ－インダゾール－７－カルボキサミド |
| WO2018191141A1 (en) | 2017-04-13 | 2018-10-18 | Janssen Pharmaceutica Nv | Combination therapy for prostate cancer |
| KR102582624B1 (ko) | 2017-04-24 | 2023-09-22 | 테사로, 인코포레이티드 | 니라파립의 제조 방법 |
| EP3615572A1 (en) | 2017-04-27 | 2020-03-04 | Tesaro Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| TWI879716B (zh) | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| AU2018270112A1 (en) * | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
| CN108530425A (zh) * | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| CN109081828B (zh) * | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 |
| US10927095B2 (en) | 2017-08-14 | 2021-02-23 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of Niraparib and intermediates thereof |
| CN111094981B (zh) * | 2017-09-13 | 2024-04-16 | B.R.A.H.M.S有限公司 | Pct和pro-adm作为监测抗生素治疗的标记物 |
| US20200271666A1 (en) * | 2017-09-13 | 2020-08-27 | B.R.A.H.M.S Gmbh | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
| WO2019053116A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | FLUID THERAPY GUIDING METHOD BASED ON PROADRENOMEDULLINE |
| KR20250016494A (ko) * | 2017-09-26 | 2025-02-03 | 테사로, 인코포레이티드 | 니라파립 제제 |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| SG11202002499TA (en) | 2017-10-06 | 2020-04-29 | Tesaro Inc | Combination therapies and uses thereof |
| SG11202006147SA (en) | 2017-12-27 | 2020-07-29 | Tesaro Inc | Methods of treating cancer |
| AU2019215450A1 (en) | 2018-02-05 | 2020-08-27 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| WO2020072797A1 (en) * | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Niraparib salts |
| US20210347758A1 (en) * | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| WO2020072860A1 (en) * | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
| WO2020225753A2 (en) | 2019-05-06 | 2020-11-12 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN110407704B (zh) * | 2019-08-19 | 2022-05-17 | 常州沃腾化工科技有限公司 | 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法 |
| UY39201A (es) | 2020-05-08 | 2021-11-30 | Janssen Pharmaceutica Nv | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib |
| US20240325369A1 (en) | 2021-07-19 | 2024-10-03 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
| AU2023214795A1 (en) | 2022-02-04 | 2024-09-19 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
| WO2024238587A1 (en) | 2023-05-17 | 2024-11-21 | Tesaro, Inc. | Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer |
| CN121443291A (zh) | 2023-08-02 | 2026-01-30 | 詹森药业有限公司 | 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌 |
| CN117843713A (zh) * | 2023-12-18 | 2024-04-09 | 上海亲合力生物医药科技股份有限公司 | 基于肿瘤微环境激活的激酶抑制剂、组合物及应用 |
| CN119707921B (zh) * | 2024-12-19 | 2026-03-03 | 四川轻化工大学 | 一种尼拉帕尼的合成方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| AT401651B (de) * | 1994-06-14 | 1996-11-25 | Biochemie Gmbh | 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4- |
| IL123147A (en) | 1995-08-02 | 2004-02-19 | Univ Newcastle Ventures Ltd | Benzamide imidazole - 4 carboxamide and their use |
| JP2002515488A (ja) | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法 |
| IL142760A (en) | 1998-10-30 | 2005-12-18 | Lonza Ag | Method for producing 4-Ä(2',5'-diamino-6'- halopyrimidine-4' -yl) aminoÜ-cyclopent -2- enyl-methanols |
| DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| DK1131301T3 (da) | 1998-11-17 | 2006-01-09 | Abbott Gmbh & Co Kg | 2-phenylbenzimidazoler og 2-phenylindoler, fremstilling af anvendelse heraf |
| CA2352554C (en) | 1998-11-27 | 2006-10-10 | Basf Aktiengesellschaft | Substituted benzimidazoles and their use as parp inhibitors |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| WO2001021615A1 (fr) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
| US6508365B1 (en) * | 1999-12-28 | 2003-01-21 | Pitney Bowes Inc. | Method of removing mail from a mailstream using an incoming mail sorting apparatus |
| WO2001057038A1 (de) | 2000-02-01 | 2001-08-09 | Basf Aktiengesellschaft | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
| DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| JPWO2002068407A1 (ja) | 2001-02-28 | 2004-06-24 | 山之内製薬株式会社 | ベンゾイミダゾール化合物 |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| JPWO2003062234A1 (ja) | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | キノキサリン化合物 |
| US20040034078A1 (en) | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| WO2004014861A1 (ja) | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キノリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| AU2004259741A1 (en) * | 2003-07-21 | 2005-02-03 | Smithkline Beecham Corporation | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| US20050288295A1 (en) * | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
| GB0327740D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| WO2005066136A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
| DK1794163T3 (da) | 2004-09-22 | 2010-04-12 | Pfizer | Fremgangsmåde til fremstilling af poly(ADP-ribose)polymeraseinhibitorer |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| KR101280096B1 (ko) | 2005-06-29 | 2013-06-28 | 컴퓨메딕스 리미티드 | 전도성 브리지를 포함하는 센서 어셈블리 |
| EP1957477B1 (en) | 2005-09-29 | 2011-12-07 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
| WO2007059230A2 (en) * | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| EP2007733B1 (en) * | 2006-04-03 | 2016-05-25 | MSD Italia S.r.l. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| CA2647373C (en) * | 2006-05-02 | 2014-03-18 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US7892667B2 (en) * | 2006-09-13 | 2011-02-22 | Altek Corporation | Battery security device |
| AR064777A1 (es) * | 2007-01-10 | 2009-04-22 | Inst Di Reserche D Biolog Mole | Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp) |
| JP2008228154A (ja) * | 2007-03-15 | 2008-09-25 | Fujitsu Ltd | 表示装置，および遠隔操作装置 |
-
2009
- 2009-01-08 JP JP2010541101A patent/JP5989965B2/ja active Active
- 2009-01-08 CN CN201610345956.4A patent/CN106008460B/zh active Active
- 2009-01-08 ES ES09700579.7T patent/ES2548131T3/es active Active
- 2009-01-08 EP EP09700579.7A patent/EP2240466B1/en active Active
- 2009-01-08 WO PCT/GB2009/000041 patent/WO2009087381A1/en not_active Ceased
- 2009-01-08 CN CN2009801018616A patent/CN101932572A/zh active Pending
- 2009-01-08 MX MX2010006593A patent/MX337421B/es active IP Right Grant
- 2009-01-08 KR KR1020107015011A patent/KR101653548B1/ko active Active
- 2009-01-08 CA CA2711491A patent/CA2711491C/en active Active
- 2009-01-08 BR BRPI0906020-0A patent/BRPI0906020A2/pt not_active Application Discontinuation
- 2009-01-08 US US12/811,922 patent/US8436185B2/en active Active
- 2009-01-08 AU AU2009203598A patent/AU2009203598B2/en active Active
- 2009-01-08 NZ NZ586675A patent/NZ586675A/en unknown
-
2010
- 2010-06-01 ZA ZA2010/03902A patent/ZA201003902B/en unknown
- 2010-06-06 IL IL206201A patent/IL206201A/en active Protection Beyond IP Right Term
-
2018
- 2018-05-14 FR FR18C1020C patent/FR18C1020I2/fr active Active
- 2018-05-15 NL NL300938C patent/NL300938I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL206201A0 (en) | 2010-12-30 |
| AU2009203598A1 (en) | 2009-07-16 |
| US20100286203A1 (en) | 2010-11-11 |
| JP5989965B2 (ja) | 2016-09-07 |
| AU2009203598B2 (en) | 2013-09-26 |
| IL206201A (en) | 2014-07-31 |
| EP2240466B1 (en) | 2015-07-29 |
| ES2548131T3 (es) | 2015-10-14 |
| EP2240466A1 (en) | 2010-10-20 |
| CN101932572A (zh) | 2010-12-29 |
| KR101653548B1 (ko) | 2016-09-02 |
| ZA201003902B (en) | 2011-02-23 |
| CA2711491A1 (en) | 2009-07-16 |
| WO2009087381A1 (en) | 2009-07-16 |
| NZ586675A (en) | 2012-04-27 |
| MX2010006593A (es) | 2010-12-21 |
| FR18C1020I2 (fr) | 2019-06-07 |
| RU2495035C2 (ru) | 2013-10-10 |
| RU2010133241A (ru) | 2012-02-20 |
| JP2011509252A (ja) | 2011-03-24 |
| NL300938I2 (nl) | 2019-01-08 |
| BRPI0906020A2 (pt) | 2015-06-30 |
| CN106008460B (zh) | 2022-08-12 |
| FR18C1020I1 (https=) | 2018-07-13 |
| US8436185B2 (en) | 2013-05-07 |
| CA2711491C (en) | 2016-03-08 |
| CN106008460A (zh) | 2016-10-12 |
| KR20100114021A (ko) | 2010-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX337421B (es) | Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida. | |
| MX2009013077A (es) | Derivados dde benzoxazolona. | |
| MY153727A (en) | Pyridazinone derivatives | |
| WO2010108187A3 (en) | Compounds and methods for treating mammalian gastrointestinal microbial infections | |
| PH12013501772A1 (en) | Inhibitors of e1 activating enzyme | |
| EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| MY157177A (en) | Heteroaryl compounds useful as inhibitors of e1 activating enzymes | |
| NZ603525A (en) | Pyrimidine based compound and uses thereof | |
| MX2009009948A (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa. | |
| GEP20125564B (en) | Pyrimidine derivatives as kinase inhibitors | |
| UA99311C2 (en) | Inhibitors of c-fms kinase | |
| MX2009012708A (es) | Derivados de piridazinona. | |
| EA201001412A1 (ru) | Ингибиторы киназы pim и способы их применения | |
| MX2010003668A (es) | Derivados de purina sustituidas con primidina. | |
| MX2010005343A (es) | Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina. | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| NZ592925A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| DE602007004618D1 (de) | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren | |
| NZ702050A (en) | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| EA200901603A1 (ru) | Арил-эфирные производные пиридазинона | |
| CU23890B1 (es) | Inhibidores heterocíclicos de estearoil-coa-desaturasa | |
| BRPI0506802A (pt) | derivados de indol e uso destes como inibidores de quinase em inibidores de ikk2 particulares | |
| MX2011012629A (es) | Inhibidores de actividad de cinasa tipo pirimidina. | |
| MX2009002842A (es) | Inhibidores heterociclicos de c-met y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: MERCK SHARP & DOHME LTD. |
|
| HC | Change of company name or juridical status |
Owner name: MERCK SHARP & DOHME LTD. |
|
| FG | Grant or registration |